Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
88.71
+1.78 (2.05%)
Sep 10, 2026, 4:00 PM EDT - Market closed
Spyre Therapeutics Employees
Spyre Therapeutics had 125 employees as of June 30, 2026. The number of employees increased by 38 or 43.68% compared to the same quarter last year.
Employees
125
Change
38
Growth
43.68%
Revenue / Employee
n/a
Profits / Employee
-$1,201,704
Market Cap
7.82B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 125 | 38 | 43.68% |
| Mar 31, 2026 | 112 | 39 | 53.42% |
| Dec 31, 2025 | 102 | 37 | 56.92% |
| Sep 30, 2025 | 95 | 35 | 58.33% |
| Jun 30, 2025 | 87 | 27 | 45.00% |
| Mar 31, 2025 | 73 | 43 | 143.33% |
| Dec 31, 2024 | 65 | 35 | 116.67% |
| Sep 30, 2024 | 60 | 46 | 328.57% |
| Dec 31, 2023 | 30 | -39 | -56.52% |
| Jun 30, 2023 | 14 | -78 | -84.78% |
| Mar 31, 2023 | 61 | -38 | -38.38% |
| Dec 31, 2022 | 69 | -32 | -31.68% |
| Sep 30, 2022 | 69 | -21 | -23.33% |
| Jun 30, 2022 | 92 | 1 | 1.10% |
| Mar 31, 2022 | 99 | 11 | 12.50% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| Ionis Pharmaceuticals | 1,480 |
| Twist Bioscience | 979 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Mirum Pharmaceuticals | 433 |
| Rhythm Pharmaceuticals | 414 |
| TG Therapeutics | 399 |
SYRE News
- 13 hours ago - Spyre Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 1 day ago - Spyre Therapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 2 days ago - Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial - TheFly
- 2 days ago - Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - GlobeNewsWire
- 6 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 7 days ago - Spyre Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 15 days ago - Spyre Therapeutics falls -13.2% - TheFly
- 15 days ago - Spyre Therapeutics falls -11.6% - TheFly